EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Post‐COVID‐19 Area Postrema Syndrome With SARS‐CoV‐2 in CSF: A Dual‐Case Report and Review of the Literature

Wan Zhu, Jing Qian, Min Peng, Yan Li, Jinghan Hu iD

Immunity, Inflammation and Disease · 2026-04 · 14 (4)

DOI: 10.1002/iid3.70421 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 06.04.2026. Verfasst von Wan Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Affiliated Hospital, People's Hospital of Wenshan Prefecture, Kunming University of Science and Technology, Wenshan, China. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Area Postrema, Neuromyelitis Optica. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wenshan Prefecture People's Hospital 2024 Annual Internal Scientific Research Key Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune astrocytopathy characterized by inflammatory demyelinating lesions in the central nervous system. Area postrema syndrome (APS), marked by intractable nausea, vomiting, and hiccups, is a recognized but less common initial manifestation. Post‐infectious autoimmunity triggered by SARS‐CoV‐2 has been increasingly associated with NMOSD pathogenesis; however, the clinical significance of direct viral neuroinvasion and its relationship to divergent patient outcomes remains poorly understood.

Methods

We report two female patients who developed isolated APS shortly after COVID‐19 infection. Both patients underwent comprehensive neurological evaluation, including brain and spinal magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis with metagenomic next‐generation sequencing (mNGS), and serological testing for aquaporin‐4 immunoglobulin G (AQP4‐IgG), myelin oligodendrocyte glycoprotein immunoglobulin G (MOG‐IgG), and glial fibrillary acidic protein immunoglobulin G (GFAP‐IgG) using cell‐based assays. Clinical outcomes were compared in the context of antibody serostatus and treatment strategies. A review of the relevant literature on post‐COVID NMOSD was also performed.

Results

Both patients presented with intractable vomiting and hiccups following SARS‐CoV‐2 infection, and MRI demonstrated isolated T2/FLAIR hyperintense lesions in the dorsal medulla consistent with area postrema involvement. SARS‐CoV‐2 RNA sequences were detected in the CSF of both patients via mNGS, suggesting direct viral neuroinvasion or blood–brain barrier compromise. Despite similar initial presentations, their outcomes diverged dramatically. Patient 1 was AQP4‐IgG negative, responded well to immunotherapy with intravenous immunoglobulin and corticosteroids followed by mycophenolate mofetil maintenance, and remained relapse‐free at 12‐month follow‐up with significant lesion regression on MRI. Patient 2 was AQP4‐IgG positive in both serum and CSF, and despite acute treatment, experienced a fatal relapse 6 months later with longitudinally extensive transverse myelitis while on low‐dose prednisone monotherapy.

Conclusions

Isolated APS may represent an important yet under‐recognized manifestation of post‐COVID‐19 autoimmune neuroinflammation. Detection of SARS‐CoV‐2 in CSF supports a role for direct viral neuroinvasion as a localized inflammatory stimulus. AQP4‐IgG serostatus serves as a critical prognostic determinant: seronegativity is associated with a benign, monophasic course, whereas seropositivity mandates prompt initiation of potent immunosuppressive therapy to prevent devastating relapses. Clinicians should maintain a high index of suspicion for NMOSD in patients with unexplained persistent vomiting following COVID‐19, and perform urgent neuroimaging and antibody testing for early risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Area PostremaNeuromyelitis OpticaHumansFemaleMiddle AgedMagnetic Resonance ImagingImmunoglobulin GAquaporin 4AutoantibodiesAdult

Stichwörter der Autor:innen

COVID‐19SARS‐COV‐2aquaporin‐4 (AQP4‐IgG)area postrema syndromeneuromyelitis optica spectrum disorder (NMOSD)

Substanzen

Immunoglobulin GAquaporin 4Autoantibodies

Autor:innen und Institutionen

  • Department of Radiology, Affiliated Hospital, People's Hospital of Wenshan Prefecture, Kunming University of Science and Technology, Wenshan, China.
  • Medical College of Kunming University of Science and Technology, Kunming, China.
  • Department of Respiratory Medicine, The First People's Hospital of Yunnan Province, Kunming, China.
  • Department of Neurology, Affiliated Hospital, People's Hospital of Wenshan Prefecture, Kunming University of Science and Technology, Wenshan, China.
  • The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.

ORCID-Profile: Jinghan Hu

Förderung

  • Wenshan Prefecture People's Hospital 2024 Annual Internal Scientific Research Key Projects

Zitieren

APA

Zhu, W., Qian, J., Peng, M., Li, Y., & Hu, J. (2026). Post‐COVID‐19 Area Postrema Syndrome With SARS‐CoV‐2 in CSF: A Dual‐Case Report and Review of the Literature. Immunity, Inflammation and Disease, 14(4). https://doi.org/10.1002/iid3.70421

Vancouver

Zhu W, Qian J, Peng M, Li Y, Hu J. Post‐COVID‐19 Area Postrema Syndrome With SARS‐CoV‐2 in CSF: A Dual‐Case Report and Review of the Literature. Immunity, Inflammation and Disease. 2026;14(4). doi:10.1002/iid3.70421

BibTeX
@article{Zhu2026,
  author = {Zhu, Wan and Qian, Jing and Peng, Min and Li, Yan and Hu, Jinghan},
  title = {Post‐COVID‐19 Area Postrema Syndrome With SARS‐CoV‐2 in CSF: A Dual‐Case Report and Review of the Literature},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/iid3.70421}
}
Kostenlos starten →